medigraphic.com
ISSN 1561-3054 (Electronic)

2015, Number 3

<< Back Next >>

Rev Cubana Med Trop 2015; 67 (3)

Hypotonic-hyporesponsive episodes after the application of vaccines in Cuba during the period 2012-2013

Galindo SBM, Concepción DD, Galindo SMA

Language: Spanish
References: 33
Page:
PDF size: 185.23 Kb.


ABSTRACT

Introduction: the use of the diphtheria, pertussis (whole cells) and tetanus vaccine started in the forties of the twentieth century considerably reduced theses diseases. Many events associated with this vaccine took place also, however. For example, the hypotonic-hyporesponsive episode, reported less frequently, to the Haemophilus influenzae Type B and hepatitis B vaccines. This is a rare and little known event.
Objective: to improve knowledge about this entity.
Methods: a retrospective observational study was performed of the hypotonichyporesponsive episodes (by level of diagnostic certainty) reported during 2012 and 2013 by the family doctor for the surveillance system of adverse events, coming from all provinces.
Results: 27 hypotonic-hyporesponsive episodes were reported. 92.6% corresponded to the pentavalent vaccine, to a rate of 3.2x105 applied doses. 74% were reported in the first twelve hours. It was observed more frequently after the first dose, for 48% and 85.4% happened in children less than six months. Fever, persistent crying, vomiting, malaise and drowsiness were the symptoms associated with to condition.
Conclusions: the surveillance of this episode has revealed the appearance time after the vaccine, dose, age and whether it is associated with other symptoms. It is a first approach to this event, to improve their knowledge, which will continue with the safety and reliability of the National Immunization Program in Cuba.


REFERENCES

  1. Vacunas e inmunización: Situación mundial. 3rd. Geneva: World Health Organization; 2009. p. 16.

  2. Escobar A, Valdespino JL, Sepúlveda J. Vacunas. Ciencia y salud. Historia de las vacunas y las vacunaciones. Colección Publicaciones técnicas del INDRE. Cap 2. México DF: Secretaria de Salud, Subsecretaria de Coordinación y Desarrollo; 1992. p. 10–20.

  3. Hinman AR. Public health considerations; in Plotkin SA, Mortimer EA (eds) Vaccine Philadelphia, Saunders; 1988. p. 587-611.

  4. Iskander J, Gidudu J, Arboleda N, Huang W. Selección de los principales problemas de seguridad de las vacunas. Ann Nestlé. 2008;66:93-102.

  5. Whitembury A, Ticona M. Eventos supuestamente atribuibles a vacunación o inmunización. (ESAVI) Rev Peruana Epidemiol. 2009 [citado 14 de diciembre de 2014];13(3). Disponible en:http://censia.salud.gob.mx/contenidos/vacunas/ESAVI_2014.pdf

  6. Thacker SB, Berkelman RL. Surveillance of Medical Technologies. J Public Health Policy. 1986;7(1):363-76.

  7. Postila V, Kilpi T. Use of vaccine surveillance data in the evaluation of safety of vaccines. Vaccine. 2004;22:2076-79.

  8. Cherry JD. Historical review of pertussis and the classical vaccine. Journal of Infectious Disease. 1996;174(supt 3):S259-S263.

  9. Cody CL, Baraff LJ, Cherry JD. Nature and rates of adverse reactions associated with DPT and DT immunizations in infants and children. Pediatrics. 1981;68:650-60.

  10. Abarca VK, Cerda LJ, Ferreccio RC. Reacciones adversas a vacunas DPT del Programa Nacional de Inmunizaciones. Rev Med Chil. Jan. 2009;137(1):10–7.

  11. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: addressing the need for standardized case defi nitions of adverse events following immunization (AEFI).Vaccine. 2002;21(3-4):298-302.

  12. Buettcher M. Hypotonic–Hiporesponsive Episode (HHE).as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis and presentation. Vaccine. 2007;25 5875-81.

  13. Rüggeberg J, Gold M, Bayas JM, Blum M, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis and presentation of immunization safety data. Vaccine. 2007;25:5675-84.

  14. Bonhoeffer J, Menkes J, Gold M, Souza-Brito G, Fisher M, Halsey N. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine. 2004;22:557–62.

  15. Sejvar J, Kohl K, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine. 2011;29 599-612.

  16. Bonhoeffer J, Vermeer P, Halperim S, Kempe A, Music S, Shindman J, et al. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine. 2004;22 586-91.

  17. Baraff LJ, Shields WD, Beckwith L, Strome G, Marcy SM, Cherry JD, et al. Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheriatetanus- pertussis immunization: follow-up evaluation. Pediatrics. 1988;81:789-94.

  18. Vermeer-de Bondt PE, Labadie J, Rümke HC. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow-up study. BMJ. 1998;316:902-3.

  19. DuVernoy TS, Braun MM. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998. Pediatrics. 2000;106:52.

  20. Rosenthal S, Chen R, Hadler S. The safety of acelular pertussis vaccine vs wholecell pertussis vaccine: a postmarketing assessment. Arch Pediatr Adolesc Med. 1996;150(5):457-60.

  21. Goodwin H, Nash M, Gold M. Vaccination of children following a previous hypotonic-hyporresponsive episode. J Paediatr Child Health. 1999;35:549-52.

  22. Gold R, Scheiffele D, Halperin S, Dery P, Law B, Lebel M, et al. Hypotonichyporresponsive episodes in children hospitalized at 10 Canadian pediatric tertiarycare centers, 1991-1994. Can Commun Dis Rep. 1997;23:73-6.

  23. Monteiro, SAMG. Avaliação dos Eventos Adversos Pós-vacina Tetravalente. Brasil, 2002 – 2005. [Dissertação de Mestrado]. Cuiabá: Instituto de Saúde Coletiva, Universidade Federal de Mato Grosso; 2007.

  24. Ferreira Lemos MC. Vigilância de eventos adversos após vacinação contra difteria, tétano, coqueluche ehaemophilus influenzae tipo b no município do Rio de Janeiro, 1998-2005. Disertación de maestria en Salud Pública; 2007.

  25. Gold MS, Kempe A, Osbourn M. A comparison of serious adverse reactions to whole cell and acelular pertussis vaccines in South Australia. Med J Aust. 1999;171:331-32.

  26. Vermeer-de Bondt PE, Van der Maas NA. The effect of age and dose number on the risk of collapse (hypotonic-hyporesponsive episode) after pertussis vaccination. Pediatr Infect Dis J. 2008;27:355-7.

  27. Blumberg DA, Mink CM, Lewis K. Pathophysiology of reactions associated with pertussis vaccine. Devlop Biol Standard. 1991;73:289-95.

  28. Vermeer-de Bondt P. Adverse events following immunisation under the National Vaccination Program of the Netherlands; RIVM reports in 1995. Bilthoven, The Netherlands; 2001.

  29. Freitas FRM. Vigilância de Eventos Adversos Pós-Vacina DPT e Preditores de Gravidade. Estado de São Paulo 1984-2001. Epidemiologia e serviços de saúde. 2007 [citado 14 de diciembre de 2014];16(2). Disponible em:http://scielo.iec.pa.gov.br/pdf/ess/v16n2/v16n2a13.pdf

  30. Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin SA, OrensteinWA, editors. Vaccines. 4th ed. Philadelphia: Saunders; 2004. p. 515.

  31. Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Überall M, Laussucq S, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis componentDTP (DTaP) vaccine, the Lederle wholecell component DTP vaccine, or DT vaccine. Pediatrics. 1998;101:1-11.

  32. Martins FR, Keico H, Sarmento CH, Figueredo BA, Pacheco MA, Waldman E, et al. Eventos adversos pós-vacina contra a difteria, coqueluche e tétanos e fatores associados a súa gravidade. Rev Saúde Publica. 2007;41(6):1032-41.

  33. Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde. Manual dos Centros de Referência para imunobiológicos especiais. J Pediatr (Rio J). 2007;83(6):523-528.




2020     |     www.medigraphic.com